# Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)

> **NCT06795204** · PHASE1 · COMPLETED · sponsor: **Haisco-USA Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Anesthesia; Adverse Effect
- Cardiac Arrhythmia

## Interventions

- **DRUG:** HSK3486
- **DRUG:** Moxifloxacin Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06795204
- **Lead sponsor:** Haisco-USA Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-09
- **Primary completion:** 2024-05-19
- **Final completion:** 2024-11-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06795204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06795204, "Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06795204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*